153 related articles for article (PubMed ID: 8890472)
1. Adenovirus-mediated transfer of human factor IX gene in immunodeficient and normal mice: evidence for prolonged stability and activity of the transgene in liver.
Yao SN; Farjo A; Roessler BJ; Davidson BL; Kurachi K
Viral Immunol; 1996; 9(3):141-53. PubMed ID: 8890472
[TBL] [Abstract][Full Text] [Related]
2. Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host.
Poller W; Schneider-Rasp S; Liebert U; Merklein F; Thalheimer P; Haack A; Schwaab R; Schmitt C; Brackmann HH
Gene Ther; 1996 Jun; 3(6):521-30. PubMed ID: 8789802
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression.
Michou AI; Santoro L; Christ M; Julliard V; Pavirani A; Mehtali M
Gene Ther; 1997 May; 4(5):473-82. PubMed ID: 9274725
[TBL] [Abstract][Full Text] [Related]
4. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.
Snyder RO; Miao CH; Patijn GA; Spratt SK; Danos O; Nagy D; Gown AM; Winther B; Meuse L; Cohen LK; Thompson AR; Kay MA
Nat Genet; 1997 Jul; 16(3):270-6. PubMed ID: 9207793
[TBL] [Abstract][Full Text] [Related]
5. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX.
Fields PA; Kowalczyk DW; Arruda VR; Armstrong E; McCleland ML; Hagstrom JN; Pasi KJ; Ertl HC; Herzog RW; High KA
Mol Ther; 2000 Mar; 1(3):225-35. PubMed ID: 10933938
[TBL] [Abstract][Full Text] [Related]
6. Primary myoblast-mediated gene transfer: persistent expression of human factor IX in mice.
Yao SN; Smith KJ; Kurachi K
Gene Ther; 1994 Mar; 1(2):99-107. PubMed ID: 7584074
[TBL] [Abstract][Full Text] [Related]
7. Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors.
Kolls JK; Lei D; Odom G; Nelson S; Summer WR; Gerber MA; Shellito JE
Hum Gene Ther; 1996 Mar; 7(4):489-97. PubMed ID: 8800743
[TBL] [Abstract][Full Text] [Related]
8. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains.
Barr D; Tubb J; Ferguson D; Scaria A; Lieber A; Wilson C; Perkins J; Kay MA
Gene Ther; 1995 Mar; 2(2):151-5. PubMed ID: 7719932
[TBL] [Abstract][Full Text] [Related]
9. Muscle as a target for supplementary factor IX gene transfer.
Hoffman BE; Dobrzynski E; Wang L; Hirao L; Mingozzi F; Cao O; Herzog RW
Hum Gene Ther; 2007 Jul; 18(7):603-13. PubMed ID: 17594244
[TBL] [Abstract][Full Text] [Related]
10. High-level factor VIII gene expression in vivo achieved by nonviral liver-specific gene therapy vectors.
Miao CH; Ye X; Thompson AR
Hum Gene Ther; 2003 Sep; 14(14):1297-305. PubMed ID: 14503965
[TBL] [Abstract][Full Text] [Related]
11. Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo.
Lieber A; He CY; Kirillova I; Kay MA
J Virol; 1996 Dec; 70(12):8944-60. PubMed ID: 8971024
[TBL] [Abstract][Full Text] [Related]
12. Constitutive expression of murine CTLA4Ig from a recombinant adenovirus vector results in prolonged transgene expression.
Schowalter DB; Meuse L; Wilson CB; Linsley PS; Kay MA
Gene Ther; 1997 Aug; 4(8):853-60. PubMed ID: 9338015
[TBL] [Abstract][Full Text] [Related]
13. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo.
Yang Y; Jooss KU; Su Q; Ertl HC; Wilson JM
Gene Ther; 1996 Feb; 3(2):137-44. PubMed ID: 8867861
[TBL] [Abstract][Full Text] [Related]
14. Increased maintenance and persistence of transgenes by excision of expression cassettes from plasmid sequences in vivo.
Riu E; Grimm D; Huang Z; Kay MA
Hum Gene Ther; 2005 May; 16(5):558-70. PubMed ID: 15916481
[TBL] [Abstract][Full Text] [Related]
15. Lack of persistence of E1- recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs.
Fang B; Wang H; Gordon G; Bellinger DA; Read MS; Brinkhous KM; Woo SL; Eisensmith RC
Gene Ther; 1996 Mar; 3(3):217-22. PubMed ID: 8646552
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response.
Christ M; Lusky M; Stoeckel F; Dreyer D; Dieterlé A; Michou AI; Pavirani A; Mehtali M
Immunol Lett; 1997 Jun; 57(1-3):19-25. PubMed ID: 9232420
[TBL] [Abstract][Full Text] [Related]
17. Hepatic control elements promote long-term expression of human coagulation factor IX gene in hydrodynamically transfected mice.
Kim HS; Kim JC; Lee YK; Kim JS; Park YS
J Gene Med; 2011 Jul; 13(7-8):365-72. PubMed ID: 21710610
[TBL] [Abstract][Full Text] [Related]
18. Linear DNAs concatemerize in vivo and result in sustained transgene expression in mouse liver.
Chen ZY; Yant SR; He CY; Meuse L; Shen S; Kay MA
Mol Ther; 2001 Mar; 3(3):403-10. PubMed ID: 11273783
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer.
Guo ZS; Wang LH; Eisensmith RC; Woo SL
Gene Ther; 1996 Sep; 3(9):802-10. PubMed ID: 8875229
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice.
Smith TA; Mehaffey MG; Kayda DB; Saunders JM; Yei S; Trapnell BC; McClelland A; Kaleko M
Nat Genet; 1993 Dec; 5(4):397-402. PubMed ID: 8298650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
